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Abstract
FGF signaling inhibits chondrocyte proliferation, a cell type-specific response that is the basis for several genetic skeletal
disorders caused by activating FGFR mutations. This phenomenon requires the function of the p107 and p130 members of
the Rb protein family, and p107 dephosphorylation is one of the earliest distinguishing events in FGF-induced growth arrest.
To determine whether p107 dephoshorylation played a critical role in the chondrocyte response to FGF, we sought to
counteract this process by overexpressing in RCS chondrocytes the cyclin D1/cdk4 kinase complex. CyclinD/cdk4-expressing
RCS cells became resistant to FGF-induced p107 dephosphorylation and growth arrest, and maintained significantly high
levels of cyclin E/cdk2 activity and of phosphorylated p130 at later times of FGF treatment. We explored the involvement of
a phosphatase in p107 dephosphorylation. Expression of the SV40 small T-Ag, which inhibits the activity of the PP2A
phosphatase, or knockdown of the expression of the PP2A catalytic subunit by RNA interference prevented p107
dephosphorylation and FGF-induced growth arrest of RCS cells. Furthermore, an association between p107 and PP2A was
induced by FGF treatment. Our data show that p107 dephosphorylation is a key event in FGF-induced cell cycle arrest and
indicate that in chondrocytes FGF activates the PP2A phosphatase to promote p107 dephosphorylation.
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Introduction
The formation and growth of long bones and vertebrae is
achieved through endochondral ossification, a strictly regulated
process that requires the proliferation and differentiation of
chondrocytes. Chondrocytes commitment, proliferation, and
differentiation are regulated by a number of signaling molecules
and transcription factors, and genetic and biochemical studies
have identified FGF signaling as a central regulator of these
processes [1]. The excessive or unregulated FGF signaling caused
by activating FGFR mutations strongly inhibits chondrocyte
proliferation and affects their differentiation, resulting in several
bone morphogenetic disorders, the best known of which is
achondroplasia [2].
The inhibition of chondrocyte proliferation induced by FGF is a
cell type-specific response that contrasts with the mitogenic effect
of FGFs in most other cells, raising the question of how the same
signaling inputs are interpreted by different cell types to generate
specific patterns of gene expression and biological response. In
chondrocytes, FGFs activate a complex network of signaling and
transcriptional events that result in growth inhibition and the
induction of some aspects of differentiation [3]. In studies aimed at
identifying the key effector molecules and events responsible for
the FGF-induced growth-arrest, we had previously established that
it requires the function of the p107 and p130 members of
Retinoblastoma (Rb) family, but not of pRb [4], in line with the
observation that p107/p130 knockout mice exhibit exaggerated
chondrocyte proliferation [5]. Furthermore, cell and organ culture
experiments suggested that p107 played the major role in the FGF
response[4]. Rb proteins are essential cell cycle regulators and
their function is regulated by phosphorylation at several Ser/Thr
residues. In the active hypophosphorylated form, Rb proteins
interact with and inhibit transcriptional activation by the E2F
family of transcription factors that control the expression of many
cycle progression genes. Phosphorylation by cyclin dependent
kinases (cdk) inactivates the Rb proteins, allowing E2F factors to
positively influence the transcription of cell cycle genes and cell
proliferation [6]. Consistent with the growth inhibitory response,
p107, p130 and pRb all become dephosphorylated upon FGF
treatment of chondrocytes, but while p130 and pRb undergo
dephosphorylation 10–12 hours after exposure of the cells to FGF,
p107 is dephosphorylated very rapidly (0.5–1 hour). p107
dephosphorylation is also observed in the presence of RNA and
protein synthesis inhibitors, indicating that it results from a
signaling event, while dephosphorylation of p130 and pRb
requires the induction of gene transcription [3]. Furthermore,
the finding that p107 dephosphorylation occurred while chondro-
cytes still exhibited robust activity of cyclin/cdk complexes and
prior to the induction of cdk inhibitors [3,7] suggested that it
resulted from the activation of a phosphatase.
While the results mentioned above suggested that p107
dephosphorylation played an important role in FGF-induced cell
cycle arrest, it is known that ectopic activation of Rb downstream
effectors, such as E2F-1, c-myc or cyclin E can bypass Rb
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hypophosphorylated Rb proteins [8–10]. Thus FGF signaling
could conceivably affect other molecules regulating cell cycle
progression and p107 dephosphorylation could have been
irrelevant to growth arrest and/or secondary to some feedback
mechanisms initiated by FGF. We have therefore investigated
whether p107 dephosphorylation was a critical event in the
growth-inhibitory response of chondrocytes to FGF. The results
presented here show that preventing p107 dephosphorylation by
the overexpression of cyclin D1/cdk4 complexes in RCS
chondrocytes abolishes the growth suppression exerted by FGF.
To determine whether a specific cellular phosphatase was
responsible for p107 dephosphorylation, we expressed the SV40
small T-Ag (ST), which is known to inactivate the PP2A
phosphatase, in RCS cells. ST expression prevents FGF-induced
p107 dephosphorylation and growth arrest, and similar results are
obtained by knock-down of PP2A expression through shRNA.
Furthermore, coimmunoprecipitation experiments show that an
association between p107 and PP2A is induced in RCS cells
shortly after FGF treatment. We conclude that p107 dephosphor-
ylation is an early and critical event in the FGF response of
chondrocytes that is mediated by PP2A. These results place PP2A
upstream of p107 dephosphorylation, adding a novel pathway to
the FGF signaling network.
Results
Overexpression of the cyclin D1/cdk4 complex prevents
p107 dephosphorylation and cell cycle arrest in FGF-
treated RCS chondrocytes
In the normal cell cycle, Rb proteins are phosphorylated by the
G1 cyclin D/cdk4 (6) and cyclin E/cdk2 kinase complexes [11,12].
While cyclin E/cdk2 can target both p107 and p130, biochemical
and genetic evidence indicates a specific requirement for cyclin
D1/cdk4 complexes for p107 inactivation. Indeed, coexpression of
cyclin D1 and cdk4, but not of the cyclin E/cdk2 complex, can
reverse a p107-induced cell cycle block [13–20]). To determine
whether p107 dephosphorylation played an important role in the
chondrocyte response to FGF, we therefore thought to counteract
the FGF-induced dephosphorylation of p107 by overexpressing
the cyclin D1/cdk4 complex. We generated RCS chondrocytic
cell lines constitutively expressing relatively high levels of cyclin D1
and cdk4 and tested how this affected p107 dephosphorylation and
the growth inhibitory FGF response. Although p107 is also rapidly
dephosphorylated upon FGF treatment of murine growth plate
primary chondrocytes (Fig. S1), RCS cells were chosen for these
experiments, as they exhibit essentially all properties of prolifer-
ating chondrocytes and allow genetic experiments that cannot be
performed in primary chondrocytes, whose life span is very
limited. Of note, we had previously shown (4) that p107 and p130
were essential FGF effectors also in RCS cells.
Retroviral vectors expressing cdk4 (FLAG-tagged) or cyclin D1
were introduced into RCS cells individually or in combination.
Cells were selected with an appropriate antibiotic and the level of
expression was determined by anti-cyclin D1, anti-cdk4, and anti-
FLAG antibodies (Fig. 1 A, B). Clones expressing moderately high
levels of cyclin D1 and cdk4 were selected for further analysis.
Three clones overexpressing both cyclin D1 and cdk4 and two
clones from either cyclin D1 or cdk4 overexpressing cells were
tested for their response to FGF.
Since activation of ERK1/2 MAP kinases contributes to the
FGF-induced growth arrest of chondrocytes and appears to be
required for p107 dephosphorylation [21], we first determined
whether these signal transduction pathways were normally
activated in our cell lines. Fig. 1C shows that a strong and
sustained activation of ERK1/2 was induced by FGF in the
parental RCS cells as well as in cells overexpressing cdk4, cyclin
D1, or both cyclin D1 and cdk4, indicating that FGF signal
transduction is intact in these cell lines.
We then determined whether cyclin D1 and cdk4 overexpres-
sion affected p107 phosphorylation and proliferation in FGF-
treated cells. Exponentially growing RCS cells contain a mixture
of hyper-and hypo-phosphorylated p107, which is completely
converted to the hypophosphorylated form within 1 hr of FGF
treatment, and remains dephosphorylated up to 24 hrs [3]. Similar
results were observed in the cell lines overexpressing cyclin D1 and
cdk4 independently. In contrast, p107 was still hyperphosphory-
lated after 24 hrs of FGF treatment when cyclin D1 and cdk4 were
coexpressed (Fig. 1D). Furthermore, overexpression of both cyclin
D1 and cdk4 clearly blocked FGF-mediated growth arrest of RCS
cells, as assayed by FACScan analysis (Fig. 1E), while introduction
of either cyclin D1 or cdk4 alone had no significant effect. We also
determined how cell proliferation was affected by FGF treatment
in RCS cells overexpressing cyclin D1 and cdk4 cells. As expected,
while the parental RCS cells ceased to proliferate within 10–
12 hours, cdk4/D1 expressing cells continued to proliferate and
increase in number (data not shown).
To support the conclusion that an enzymaticaly active cyclin
D1/cdk4 complex is necessary to overcome growth inhibition by
FGF we overexpressed several mutant forms of cdk4 defective in
cyclin D1 binding together with wild type cyclin D1 (Fig. 1A, F).
All mutants were characterized by great reduction in kinase
activity toward Rb-GST fusion protein as assayed in vitro [22,23].
We introduced a Lys22 to Ala (cdk4K22A) mutation and a triple
mutation His281, Lys282, Arg283 to Ala (cdk4H281-3A). Both
mutations also affected binding of p16INK4a cdk inhibitor (p16) to
cdk4, since cyclin D1 and p16 have overlapping binding sites on
cdk4. We also introduced two mutants (cdk4G15A and
cdk4R55A) that are defective in binding to cyclin D1, but still
retain high affinity for the p16. Expression of all of these mutants
did not prevent the FGF-induced dephosphorylation of p107
(Fig. 1F and data not shown) and FACScan analysis showed that
these cell lines were growth-inhibited upon FGF treatment
(Fig. 1G), indicating that an active D1/cdk4 complex is required
to overcome the FGF-inhibitory effect. We can also exclude that
overexpressed D1/cdk4 complexes simply sequester p16 because
the cdk4G15A and cdk4R55A mutants were still unable to prevent
FGF-mediated growth arrest.
In conclusion, these results indicate that constitutive overex-
pression of the cyclinD1/cdk4 complex in RCS cells blocks FGF-
induced p107 dephosphorylation and growth arrest, consistent
with the hypotheses that p107 dephosphorylation is a crucial initial
event in the response of chondrocytes to FGF signaling.
Interestingly cyclin D1 expression is significantly induced by
FGF in RCS cells [3], (Fig. 1B), but overexpression of cdk4 alone
has only a minimal effect on p107 dephosphorylation and growth
arrest. Since cyclin D1 is induced with relatively slow kinetics, it is
likely that a high D1/ cdk4 activity has to be present at the time of
first exposure to FGF, to prevent the cascade of events initiated by
p107 dephosphorylation.
Overexpression of cyclin D1 and cdk4 also affects later
events in the FGF response
The maintenance of FGF-induced growth arrest is character-
ized by the accumulation of hypophosphorylated p130 by 10–
16 hrs of FGF treatment, that follows a dramatic drop in cyclin E/
cdk2 activity between 6 and 12 hrs [3]. We therefore investigated
the phosphorylation status of p130 in the cells overexpressing both
p107 Dephosphorylation by PP2A
PLoS ONE | www.plosone.org 2 October 2008 | Volume 3 | Issue 10 | e3447Figure 1. Overexpression of an active cyclin D1/cdk4 complex prevents p107 dephosphorylation and cell-cycle arrest in FGF-
treated RCS. Cyclin D1 and cdk4 were stably introduced into RCS cells either independently or in combination and these cell lines were treated with
FGF1 for the indicated periods of time. 20 mg of total protein from all indicated cell lines were analyzed by SDS-PAGE followed by immunoblotting.
Equal amount of protein loading was confirmed by a-tubulin immunodetection. (A) Anti-FLAG antibodies identify two bands in the cell lines
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phosphorylated in this cell line, while FGF caused dephosphor-
ylation of p130 when cdk4 or cyclin D1 were overexpressed
independently (Fig. 2A.) Several reports [16,18,19] indicate that
the cyclin D1/cdk4 complex can phosphorylate both p107 and
p130, but that inactivation of p130 requires the phosphorylation of
additional sites by the cyclin E/cdk2 complex. We therefore
studied the activity of the cyclin E/cdk2 complex in our cell lines.
Anti-cyclin E antibody was used to immunoprecipitate cyclin E/
cdk2 complexes from protein lysates derived from untreated cells
or cells treated with FGF for 24 hrs. The immunoprecipitated
complexes were then tested for their ability to phosphorylate
histone H1 substrate in vitro. As shown in Fig 2B–D, after 24 hrs of
the FGF treatment cyclin E/cdk2 activity was drastically reduced
in FGF-treated RCS cells, cyclin D and cdk4 cells, but D1/cdk4
cells retained about 60% of cyclinE/cdk2 activity. A time course
experiment (Fig. 2D) showed that after 1 hr of FGF treatment
RCS cells retained most cyclinE/cdk2 kinase activity, similar to
D1/cdk4 cells. However, after 8 hrs of FGF treatment the cyclin
E/cdk2 kinase activity of RCS cells dropped dramatically,
becoming essentially nil at 24 hrs, while D1/cdk4 cells retained
substantial cyclinE/cdk2 activity, even after 24 hrs of FGF
treatment. Since cdk2 also complexes with cyclin A[11], which
is induced in S phase slightly later than cyclin E, we tested the
activity of cyclin A/cdk2 complexes. Similarly to cyclin E/cdk2,
cyclin A/cdk activity was strongly reduced by FGF treatment in
the parental RCS cells, but remained high in the D1/cdk4 cells
(Fig. 2 E, F).
FGF treatment of RCS cells is accompanied by down regulation
of cdk2 and up regulation of the cdk2 inhibitor p21[3,7]. Fig. 2G
shows that the level of cdk2 expression in D1/cdk4 cells after
24 hrs of FGF treatment was slightly elevated compared to RCS,
cdk4 or cyclin D1 RCS cell lines, while the increase in p21
expression was undistinguishable among experimental cell lines
(Fig. 2G). Thus these results indicate that overexpression of active
cyclinD1/cdk4 complexes not only prevents the dephosphoryla-
tion of p107 but also allows higher sustained levels of cyclinE/cdk2
activity, that may contribute to maintaining p107 and p130 in the
hyperphosphorylated state as well as cell cycle progression.
PP2A inhibition prevents p107 dephosphorylation and
FGF-induced cell cycle arrest
The regulation of Rb protein family phosphorylation by cyclin/
cdk kinases is fairly well understood, but much less is known about
the phosphatases that dephosphorylate Rbs during the normal cell
cycle or in response to exogenous signals. Since previous results
[3,7] indicated that p107 dephosphorylation occurred when FGF-
treated chondrocytes still express robust cyclin/cdk activity, we
investigated the hypothesis that the induction of p107 dephos-
phorylation by FGF resulted from the activation of a phospha-
tase[3]. We immunoprecipitated p107 from FGF-treated and
untreated RCS cells and measured p107-associated serine/
threonine phosphatase activity. Immunoprecipitates of FGF-
treated cells showed a two-three-fold increase in phosphatase
activity compared to controls (discussed later), consistent with the
hypothesis that FGF targets a phosphatase to p107.
We then determined whether inhibition of phosphatase activity
affected the p107 status in FGF-treated RCS cells, using okadaic
acid (OA) or calyculin A which are potent inhibitors of protein
phosphatases [24]. As shown in Fig. 3A, p107 dephosphorylation
was significantly prevented in the presence of OA, or calyculin A.
PP2A is an abundant and ubiquitous Ser/Thr phosphatase that
plays a role in numerous signaling pathways [25] and has been
implicated in regulation of Rb-protein phosphorylation [26–30].
PP2A has a trimeric structure consisting of a catalytic C subunit, a
scaffolding A subunit (PR65), and a variable third regulatory B
subunit which is represented by 4 different families, including at
least twenty four different proteins, that play a role in substrate
recognition and subcellular localization [31]. PP2A activity can be
blocked in vivo and in vitro by chemical inhibitors, such as OA and
calyculin A, or through interaction of PP2A with the small T-
antigen (ST) of SV40 virus [32,33], that forms a stable complex
with the A subunit, thereby competing with regulatory B subunits.
To determine if PP2A plays a role in the FGF-induced
dephosphorylation of p107, we infected RCS cells with adenovirus
vectors overexpressing GFP, ST or a mutant form of ST
(Cys97Ser) [34] which is unable to bind and inhibit PP2A
(Fig. 3B). Expression of ST inhibited p107 dephosphorylation in
FGF treated cells almost completely, while the mutant form of ST
failed to prevent it (Fig. 3C). As shown by BrdU incorporation,
FGF caused strong inhibition of DNA synthesis in RCS cells and
in Ad-GFP cells (Fig. 3D, E). However, adenovirus-driven
expression of ST overcame the FGF growth inhibitory effect
(Fig. 3D, F) which was not the case when the mutant form of ST
was expressed (Fig. 3D, G). These results strongly suggest that
PP2A plays an essential role in the dephosphorylation of p107 and
the cell cycle arrest induced by FGF.
To confirm this conclusion, we sought to knockdown PP2A
expression using RNA interference (Fig. 4). We infected cells with
the pSilencer 5.1-U6 Retrovirus, containing shRNA sequences
specific for the a isoform of the rat PP2A catalytic subunit. A
comparable retrovirus expressing scrambled shRNA was used as
control. Two sequences (shRNA 1 and 2, described in Materials
and Methods) were found to reduce the expression of the PP2A-C
protein by about 70% (Fig. 4A) and were used for further
experiments. PP2A knockdown has been reported to trigger cell
death in a variety of cell types [35], and we observed a similar
effect in our experiments, precluding the isolation of cell clones
with permanent PP2A knockdown. We therefore infected RCS
cells with the shRNA retroviruses, selected shRNA expressing cells
with puromycin for 3–4 days, and one day later determined PP2A-
C levels and the cell response to FGF treatment.
p107 was dephosphorylated within the first hour following FGF
treatment of cells expressing the scrambled shRNA. In contrast,
knockdown of PP2A-C resulted in a substantial delay (up to
12 hrs) in p107 dephosphorylation (Fig. 4B). Furthermore, cells
with reduced levels of PP2A-C retained about 80% of the original
level of BrdU incorporating cells compared to about 10% in the
control cell line (Fig. 4C), indicating that these cells are still
progressing through the cycle even in the presence of FGF.
Although the results of PP2A-C knockdown were not as
dramatic as those obtained with SV40ST, probably because the
overexpressing FLAG-tag cdk4. Both bands are equally recognized by anti-cdk4 antibody (data not shown). (B) Cyclin D1 is upregulated upon FGF
treatment in all cell lines. (C) ERK1/2 phosphorylation is activated in a similar manner in all experimental cell lines. (D, F) Western blots with anti-p107
antibodies. Hyper-and hyposphosphorylated forms of p107 are indicated. (E, G) FACScan
TM analysis of RCS cells overexpressing cdk4, cyclin D1 or
cyclin D1 and wild type or mutant cdk4 in response to FGF treatment. (E) Numbers on the Y-axis indicate percentage of total cells in G1, S and G2-M
phases. (G) In all mutant forms of cdk4 the indicated amino acids were substituted by alanine. Changes in the levels of S-phase cells are indicated.
Several clones of each cell type were used with essentially identical results.
doi:10.1371/journal.pone.0003447.g001
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PLoS ONE | www.plosone.org 4 October 2008 | Volume 3 | Issue 10 | e3447Figure 2. Effect of cyclin D1/cdk4 overexpression on p130 phosphorylation and cyclin E/cdk2 and cyclin A/cdk 2 kinase activities.
Parental RCS, cyclin D1, cdk4 or cyclin D1/cdk4 cell lines were treated with FGF1 for the indicated times. (A) p130 dephosphorylation is prevented in
cyclin D1/cdk4 expressed cells. 100 mg of total protein was analyzed by SDA-PAGE followed by immunoblotting with anti p130-antibodies. (B, D, E)
Kinase activity of immunoprecipitated cyclin E/cdk2 and cyclin A/cdk 2 complexes as assayed in vitro. The cyclin E/cdk2 and cyclin A/cdk 2 complexes
were isolated using anti-cyclin E and anti-cyclin A antibodies and histone H1 was used as a substrate. Antibody to mouse IgG was used as negative
control. Equal amount of protein loading was confirmed by immunodetection of cdk 2 in immunoprecipitated complexes. (C, F) Summary of results
from 3 independent experiments depicting relative levels of cyclinE/cdk2 and cyclin A/cdk2 activities upon FGF treatment in different cell lines. (G)
20 mg of total protein were analyzed by WB, with antibodies against cdk2 or p21. Equal amount of protein loading was confirmed by a-tubulin
immunodetection.
doi:10.1371/journal.pone.0003447.g002
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population of cells with substantially reduced levels of PP2A, the
prevention of the FGF-induced p107 dephosphorylation and
growth arrest we observed was significant and reproducible in
independent experiments. We therefore conclude that PP2A
function is required for the dephosphorylation of p107 and
consequent growth arrest induced by FGF in RCS chondrocytes.
FGF induces an association of PP2A with p107 in RCS
chondrocytes
To gain additional evidence for the hypothesis that FGF targets
PP2A to p107 and causes p107 dephosphorylation, we immuno-
precipitated either p107 or the PP2A-C subunit from FGF-treated
RCS cells and determined whether an association between
endogenous p107 and PP2A was induced by FGF treatment.
Figure 3. FGF-induced dephosphorylation of p107 is prevented by protein phosphatase inhibitors and by SV40 small t-antigen (st
SV40). (A) RCS cells were pretreated with either okadaic acid (OA) or Calyculin A 2 hours before FGF treatment. 20 mg of total protein were subjected
to SDS-PAGE following inmmunodetection of p107. (B–G) RCS cells were infected with adenoviruses expressing GFP, st SV40 or st SV40 mutant C97S
following FGF1 treatment as indicated. (B,C) 20 mg of total protein were used for immmunodetection of (B) st SV40 and (C) p107. Equal amount of
protein loading was confirmed by a-actin immunodetection. (D–G) BrdU incorporation assay of FGF treated or untreated RCS cells expressing either
GFP, st SV40, or st SV40 C97S mutant. BrdU was detected by using BrdU antibodies (red). Nuclei were stained with DAPI (blue). (D) Summary of results
in panels E–G.
doi:10.1371/journal.pone.0003447.g003
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p107 and PP2A could be detected, immunoprecipitation of PP2A-
C from FGF-treated RCS brought down small but significant
amounts of P107, most prominent at 1.5 and 3 hrs after FGF
addition. As expected, PP2A-A subunits were also detected
together with the C-subunits. Consistent with this result antibodies
directed against p107 also immunoprecipitated PP2A-A and C
subunits from FGF-treated cells but not from untreated cells
(Fig. 5B). Interestingly, the association of PP2A with p107 induced
by FGF is transient, and is almost undetectable after 6 hours of
FGF treatment. This coincides with the increase in phosphatase
activity that coimmunoprecipitates with p107 in FGF-treated cells,
that also subsides at that time (Fig. 5C). This finding suggests that,
although p107 is dephosphorylated rapidly and remains dephos-
phorylated for more than 24 hours after FGF treatment, the
association of PP2A with p107 is transient and is no longer
required to keep p107 in an hypophosphorylated state at later
times, possibly because FGF signals are downregulated and/or the
Figure 4. Knockdown of PP2A catalytic subunit inhibits FGF-
induced p107 dephosphorylation. RCS cells were infected with
retroviruses encoding either 2 different sequences specific for the a-
isoform of PP2A-C subunit (shRNA1 and shRNA2) or scrambled shRNA
and treated with FGF1. 20 mg of total protein were subjected to SDS-
PAGE for inmmunodetection of (A) PP2A-C or (B) p107. (C) Percentage
cells labeled by BrdU in the cell lines with knockdown of PP2A-Ca upon
FGF treatment.
doi:10.1371/journal.pone.0003447.g004
Figure 5. FGF induces an association between endogenous
PP2A and p107. RCS cells were treated with FGF1 for the indicated
periods of time. Lysates were prepared and normalized by the amount
of total protein and subjected to immunoprecipitation with anti-PP2A-C
(A) or anti-p107 agarose conjugated (B) antibody as described in
Materials and Methods. 10% input and 50% IP samples were analyzed
by WB with anti-PP2A-C, anti-PP2A-A or anti-p107 antibody. Control
immunoprecipitation (*) was done using agarose A beads. (C) p107
immunoprecipitates from untreated and FGF treated RCS cells were
used in in vitro Ser/Thr phosphatase assay. The background (protein A
Sepharose without antibodies) was subtracted from initial counts and
this value was normalized to one in the absence of FGF treatment.
doi:10.1371/journal.pone.0003447.g005
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such time.
Taken together these results and those discussed in the previous
section support the hypothesis that in chondrocytes FGF signaling
activates a known or yet to be discovered PP2A regulatory subunit,
that would target PP2A to p107 . Indeed PP2A has been shown to
promote myc dephosphorylation by a similar mechanism [36]. It is
worth noting that the PR59/B subunit of PP2A has been reported
to target PP2A to p107 [27], but our experiments have failed so far
to detect an association between the PP2A-A and PR59 in both
untreated and FGF-treated RCS cells. We were also unable to
identify PR59 as part of the PP2A holoenzyme purified from RCS
cells (data not shown). Recent work from Magenta et al. [30] has
demonstrate that PP2A holoenzyme containing the PR70(PR48)
subunit is responsible for pRb dephosphorylation and DNA
synthesis inhibition induced by oxidative stress. However in our
preliminary experiments the PR70 subunit was barely detectable
in RCS cells and no association with p107 was detected either in
FGF-treated or untreated cells (data not shown).
In an attempt to narrow down the search for the putative
regulatory B subunit activated by FGF, we have expressed the
adenovirus E4orf4 protein, which is thought to interact with a subset
of intact PP2A holoenzymes that contain either B55a or B56 family
members [37,38] in RCS cells (Fig. 6). Coimmunoprecipitation
experiments showed that the E4orf4 protein formed stable complexes
with the PP2A A and C subunits (Fig. 6A). In FGF-treated RCS cells
overexpressing E4orf4, p107 dephosphorylation was delayed up to
11 hrs, while in parental RCS cells p107 was completely dephos-
phorylated in 1 hr (Fig. 6B). However, by 24 hrs the dephosphor-
ylation of p107 in the presence of E4orf4 was complete and cell
proliferation was arrested (data not shown). These experiments
therefore suggest that B55a or B56 containing PP2A complexes may
be specifically involved in p107 dephosphorylation, but the
mechanism of action of E4orf4 is not completely understood, and
some general impairment of PP2A function cannot be excluded.
Thus while these results are consistent with the hypothesis that PP2A
function is required for p107 dephosphorylation, the identification of
the specific regulatory subunit involved will require further studies.
Figure 6. Expression of adenovirus E4orf4 protein strongly delays p107 dephosphorylation induced by FGF. FLAG-tag E4orf4 was
stably introduced into RCS cells. Growing cultures were treated with FGF1 for indicated periods of time. (A) E4orf4 forms a stable complex with PP2A
when overexpressed in RCS cells. RCS cells overexpressing FLAG-tag E4orf4 and the parental cell line were treated with FGF. E4orf4 was
immunoprecipitated with ANTI-FLAGH M2-Agarose and immunoprecipitated complexes were analyzed using PP2A-A, PP2A-C or FLAG antibodies as
indicated. PP1 antibody was used as a negative control. As a reference 5% of the immunoprecipitated whole cell extract (‘‘input’’) was loaded. (B)
20 mg of total protein were subjected to immunodetection by p107 antibody.
doi:10.1371/journal.pone.0003447.g006
p107 Dephosphorylation by PP2A
PLoS ONE | www.plosone.org 8 October 2008 | Volume 3 | Issue 10 | e3447Discussion
The results presented in this report are consistent with the notion
that the dephosphorylation of p107 induced by FGF in chondro-
cytes initiates a cascade of events that leads to inhibition of cell
proliferation. Preventing p107 dephosphorylation in FGF-treated
cells, whether by overexpression of a p107 kinase or by inactivation
of the PP2A phosphatase, also prevents FGF-induced cell cycle
arrest, dephosphorylation of p130, and downregulation of cyclin E/
cdk2 and cyclin A/cdk2 activity. The finding that preventing p107
dephosphorylation by overexpression of the cdk4/cyclinD complex
also results in higher cdk2/cyclinE activity is consistent with the
hypothesis that the activation of p107 by FGF signaling induces its
association with E2F4 to produce transcriptionally repressive
complexes that inhibit the expression of genes required for cell
cycle progression [39]. Since both cdk2 and cyclinE have been
reported to be E2F targets [40,41], the downregulation of cyclinE/
cdk2 expression and/or activity in FGF-treated chondrocytes could
result from the activation of p107. The inhibition of p107
dephosphorylation by D1/cdk4 overexpression would thus result
inmaintaininghighlevelsofcyclinE/cdk2activityand consequently
p130 phosphorylation. Additionally, the overexpressed cyclin D1
and cdk4 could sequester p21 and p27, therefore reducing the
repression of the cyclin E/cdk2 activity by these kinase inhibitors.
Indeed it has been recently reported [42] that mice which are
mutant for both p107 and p27 function display a phenotype of
exaggerated chondrocyte proliferation very similar to that of p107/
p130 knockouts, supporting the notion that the increase in p130
phosphorylation we observe by preventing p107 dephosphorylation
would result from enhanced cdk2/cyclin E activity, and that p130
reinforces the cell cycle exit decision made by p107.
In conclusion, p107 dephosphorylation appears to be an early and
necessary event in the induction of cell cycle arrest by FGF. These
results identify p107 dephosphorylation as a decisive event in FGF-
induced growth arrest, and indicate that FGF signaling does not
directly target downstream effectors of Rb protein function, such as
E2F1 or cyclin E. Interestingly, these phenomena are cell type-
specific. In fibroblasts, where FGF signaling is a potent mitogen, FGF
does not induce p107 dephosphorylation and actually increases its
phosphorylation when applied to quiescent cells.
It is clear however that FGFsignaling utilizes multiple mechanisms
to inhibit chondrocyte proliferation, most of which are probably
necessary but not sufficient to induce growth arrest [43]. FGF
signaling induces the expression of cdk inhibitors, particularlyp21 but
also p27 and p57, and the induction of these cell cycle inhibitors is
likely to contribute to the FGF-induced growth arrest, and to Rb
protein dephosphorylation. However these events occur late after
FGF treatment, after p107 dephosphorylation has already taken
place, require new RNA and protein synthesis, and thus are likely to
play a role in the late stages of the FGF response, that we had defined
as ‘‘maintenance of growth arrest’’[3]. STAT1 and AKT activities
are also important for FGF-induced growth inhibition [44,45].
However, also in this case our results indicate that the roles played by
STAT1 and AKT in this process aredirected toward the late stagesof
the FGF-response. Clearly, elucidating the complex and probably
multiple mechanisms by which FGF inhibits chondrocyte prolifera-
tion and the cross-talk between these seemingly independent
pathways will require further studies.
Another novel and interesting finding was that inhibiting the
function of PP2A, whether by expression of the SV40 ST or by
knockdown of the PP2A catalytic subunit by shRNA, prevented
FGF-induced dephosphorylation of p107 and cell cycle arrest.
Together with the results showing that FGF induces an association
between PP2A and p107 in RCS cells, these findings suggest that
FGF signaling activates PP2A to target p107 for dephosphorylation.
It has been shown that PP2A can dephosphorylate p107 in vitro
[27],buttheregulationofPP2A activityisvery complexandstillnot
fully understood [31]. It is interesting to note that the association of
p107 with PP2-A that is induced by FGF is transient, and limited to
the first 5–6 hours of FGF treatment. This suggests that, once
dephosphorylated, p107 is no longer a target for PP2A and that the
perturbation of cell cycle progression induced by p107 dephos-
phorylation is no longer reversible. PP2A has been previously
implicated in Rb protein dephosphorylation, particularly under
conditions characteristic of stress response (UV, H2O2, etc.), and
thus it is possible that PP2A may not be the phosphatase that
normally dephosphorylates p107 in the cell cycle, but it could be
recruited for this taskonly under special conditions. At this point the
Ser/Thr residues that are initially dephosphorylated may not be the
same that are dephosphorylated during the normal cell cycle [46]
and the kinetics of dephosphorylation could also be different.
It could be argued that PP2A has been shown to regulate many
signal transduction pathways and it could play a role in other
processes that are important for p107 dephosphorylation. Thus the
effect of inhibiting PP2A function on p107 dephosphorylation could
be indirect. There are many growth-related processes in which
PP2A appears to play a role, including the regulation of the G2-M
transition, control of translation, c-myc stability, ERK1/2 activa-
tion, AKT phosphorylation and Wnt signaling [31]. However the
cell cycle block induced by FGF in chondrocytes affects mainly the
G1/S transition, overall translation and c-myc expression are not
affected until very late after FGF treatment, and the inhibition of
PP2A activity would be expected to increase ERK1/2 activation,
while ERK1/2 inhibition reduces p107 dephosphorylation and the
FGF-induced growth arrest [21]. Thus the only known effect of
PP2A that could conceivably impact on the growth-inhibitory
response of chondrycytes to FGF is its down-regulation of AKT
phosphorylation. AKT activity is reduced in FGF-treated RCS cells
and expression of a constitutively activated AKT partially relieves
the FGF growth inhibitory response [45]. However the growth-
promoting effect of activated AKT in RCS chondrocytes is minimal
when compared to the effect of PP2A inhibition, and does not
influence p107 dephosphorylation. Furthermore, we did not detect
any increase in AKT phosphorylation in RCS cells expressing
PP2A-specific shRNA when compared to controls, with or without
FGF treatment. Thus the simplest interpretation of our results is
that FGF treatment of chondrocytes results in the recruitment of
PP2A to perform p107 dephosphorylation.
In conclusion, our results identify a novel role of PP2A on
regulation of chondrocyte proliferation, that intervenes early and
upstream of p107 dephosphorylation to mediate FGF-induced
growth arrest. We are investigating the hypothesis that FGF
‘‘activates’’ a specific regulatory subunit of PP2A that would target
this phosphatase to p107 (Fig. 7). The identification of this
regulatory subunit and its mechanism of activation by FGF may
provide important clues for the understanding of PP2A regulation
as well as of the cell type-specific mechanisms that distinguish the
FGF response of chondrocytes from that of other cell types.
Materials and Methods
Cell culture, proliferation assay and FACS analysis
Rat chondrosarcoma (RCS) cells [47] were maintained in
DMEM supplemented with 10% fetal calf serum at 37uC and 9%
CO2. Cells were treated with FGF1 (5 ng/ml) (a kind gift from M.
Mohamadi, NYU) and heparin (5 mg/ml) in the absence of
antibiotics. For proliferation assay RCS cells were incubated for
2 hrs in the presence of 2 mg/ml of BrdU. Incorporation of BrdU
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performed as described previously (Laplantine, et al., 2002).
Plasmids
Rat cyclin D1 was introduced into pLXSN vector between EcoRI
and BamH1 sites. Cdk4/pBABEpuro construct was made by
inserting the PCR product into pBABEpuro vector between BamH1
and EcoRI sites. The PCR product coding human cdk4 was
obtained from pCMVcdk4 plasmid (a kind gift from M. Pagano,
NYU) using primers 59-ATATGGATCCACCATGGATTA-
CAAGGACGACGATGACAAGATGGCTACCTCTCGATAT-
GAGCCAGTGGC-39 and 59-TATAGAATTCTCACTCCG-
GATTACCTTCATCCTTAT-39. (FLAG-tag is underlined).
Plasmids containing mutant forms of cdk4 were generated using
‘‘Quik-Change Site-Directed Mutagenesis Kit’’ (Stratagene) on the
base of cdk4/pBABEpuro plasmid as specified by the manufacturer.
shRNA constructs were made according to manufacture procedure
(Ambion), using pSilencer
TM 5.1-U6 Retro vector. shRNA1 and
shRNA2 target sequences which are complementary to nucleotides
465–483 and 299–317 of rat PP2A catalytic subunit a-isoform
(NCBI accession #NM_017039). E4orf4-FLAG construct was
obtained from FLAG.E4orf4/pcDNA3 vector (a kind gift from
Josee N. Lavoie, University Laval, Quebec) by inserting the PCR
product into pBABE-puro vector between the BamHI and EcoRI
sites.
Retroviral and adenoviral infection
Retroviral infection was performed as described previously [21].
For adenoviral infection, chondrocytes were trypsinized, resus-
pended in TRIS buffer at final concentrationof 2610
6 cells/ml and
exposed to 10 pfu/cell of Ad-GFP, Ad-ST SV40 or Ad- ST SV40
mutant Cys97Ser in suspension for 1 hr at room temperature. After
20 hrs cells were treated with FGF and heparin as indicated.
Immunoprecipitation, Western blot analysis and in vitro
kinase and phosphatase assays
Protein lysates were prepared using modified RIPA buffer
(50 mM Tris HCl pH 7.4, 150 mM NaCl, 10 mM KCl, 1% NP-
40, 1 mM EDTA) in the presence of 1 mM Na3VO4,1 0m M
NaF, 1 mM PMSF and 5 mg/ml aprotinin. For immunoprecip-
itation 0.5 mg of total protein was pre-cleared by incubating for
30 min at 4uC with Protein G-SepharoseH 4B Conjugate
(ZYMED), and then incubated with 2 mg of antibody overnight
at 4uC. Protein G-Sepharose was added for 1 h at 4uC and the
immune complexes were washed 3 times with 1 ml of modified
RIPA buffer. Immunoprecipitates with antibodies against p107
and PP2A-C catalytic subunit were prepared from 1 mg of total
protein and 5 mg of antibody. NaF was omitted from RIPA buffer
for these experiments. Protein A-Sepharose was added when anti-
PP2A-C antibodies were used. Immunoprecipitates were resolved
on SDS-PAGE and analyzed by immunoblotting. The following
antibodies were used: anti-a-actin (AC-40), anti-a-tubulin (clone
B-5-1-2) and anti-FLAG M2 (Sigma), anti-p130 (BD Transduction
Laboratories), anti-cyclinD1, anti-PP2A-A subunit and anti-
phospho p42/p44 MAP kinase (Cell Signaling), anti-cdk4
(Chemicon International), anti-ST SV40 (Calbiochem), anti-
p107 (C-18), anti-p21 (C-19), anti-cyclin E (M-20), anti-cyclin
D1 (72-13G) anti-cyclin A (H432), anti-cdk2 (M2) (Santa Cruz
Biotechnology), anti-PP2A-C subunit (Millipore). The determina-
tion of cyclin E/cdk2 and cyclin A/cdk 2 activities on histone H1
was done using anti-cyclin E and anti-cyclin A antibodies as
described previously [3] . Immunoprecipitates for protein Ser/Thr
phosphatase assay (New England BioLabs) were prepared as
described above for the co-immunoprecipitation experiments.
After the final wash, immunoprecipitates were washed once more
with the phosphatase assay buffer (50 mM Tris HC1 pH 7.4,
0.1 mM Na2EDTA, 5 mM DTT, 0.0% Brij 35) and the pellet was
resuspended in the same buffer (40 ml total volume). 10 mlo f
labeled substrate (myelin basic protein) was added to initiate
reaction. Reaction mixtures were incubated for 10 min at 30uC.
The reactions were terminated by adding 200 ml of cold 20%
TCA and incubated 15 min on ice. After 5 min centrifugation at
12,0006g 200 ml of the TCA supernatant were counted in 5 ml of
scintillation fluid. The background (protein A Sepharose without
antibodies) was subtracted from initial counts and the values
obtained were normalized to the results obtained in the absence of
FGF treatment.
Figure 7. A model for FGF regulation of p107 phosphorylation in RCS cells. FGF signaling activates a regulatory B subunit that targets the
PP2A holoenzyme to p107.
doi:10.1371/journal.pone.0003447.g007
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Figure S1 FGF-induced p107 dephosphorylation and ERK1/2
activation in primary chondrocytes. Chondrocytes were isolated
from femoral and tibial growth plates of 10-day old mice, plated in
6-well plates and after 48 hours were treated with FGF1 for
2 hours (10 ng/ml). The cells were collected directly in 300 ml
2XSDS buffer and analyzed by SDS-PAGE followed by
immunoblotting against anti-p107 and anti-phospho-ERK1/2
antibodies. Hyper-and hyposphosphorylated forms of p107 are
indicated. Equal amount of protein loading was confirmed by a-
tubulin immunodetection.
Found at: doi:10.1371/journal.pone.0003447.s001 (5.70 MB TIF)
Acknowledgments
We thank R. Grassi, G. Fan, L. Cornivelli, and F. Filicori for their help in
some of the experiments, L. Dailey and A. Mansukhani for critical reading
of the manuscript. We also thank K. Rundell and R. Schneider for
providing us with recombinant adenovirus vectors.
Author Contributions
Conceived and designed the experiments: VK CB. Performed the
experiments: VK EL. Analyzed the data: VK EL CB. Wrote the paper:
VK CB.
References
1. Ornitz DM (2005) FGF signaling in the developing endochondral skeleton.
Cytokine Growth Factor Rev 16: 205–213. Epub 2005 Apr 2001.
2. Aviezer D, Golembo M, Yayon A (2003) Fibroblast growth factor receptor-3 as a
therapeutic target for Achondroplasia–genetic short limbed dwarfism. Curr
Drug Targets 4: 353–365.
3. Dailey L, Laplantine E, Priore R, Basilico C (2003) A network of transcriptional
and signaling events is activated by FGF to induce chondrocyte growth arrest
and differentiation. J Cell Biol 161: 1053–1066.
4. Laplantine E, Rossi F, Sahni M, Basilico C, Cobrinik D (2002) FGF signaling
targets the pRb-related p107 and p130 proteins to induce chondrocyte growth
arrest. J Cell Biol 158: 741–750.
5. Cobrinik D, Lee MH, Hannon G, Mulligan G, Bronson RT, et al. (1996) Shared
role of the pRB-related p130 and p107 proteins in limb development. Genes
Dev 10: 1633–1644.
6. Dyson N (1998) The regulation of E2F by pRB-family proteins. Genes Dev 12:
2245–2262.
7. Aikawa T, Segre GV, Lee K (2001) Fibroblast growth factor inhibits
chondrocytic growth through induction of p21 and subsequent inactivation of
cyclin E-Cdk2. J Biol Chem 276: 29347–29352.
8. Alevizopoulos K, Vlach J, Hennecke S, Amati B (1997) Cyclin E and c-Myc
promote cell proliferation in the presence of p16INK4a and of hypopho-
sphorylated retinoblastoma family proteins. Embo J 16: 5322–5333.
9. Qin XQ, Livingston DM, Ewen M, Sellers WR, Arany Z, et al. (1995) The
transcription factor E2F-1 is a downstream target of RB action. Mol Cell Biol 15:
742–755.
10. Wei Y, Jin J, Harper JW (2003) The cyclin E/Cdk2 substrate and Cajal body
component p220(NPAT) activates histone transcription through a novel LisH-
like domain. Mol Cell Biol 23: 3669–3680.
11. Zarkowska T, Mittnacht S (1997) Differential phosphorylation of the
retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem 272:
12738–12746.
12. Lundberg AS, Weinberg RA (1998) Functional inactivation of the retinoblas-
toma protein requires sequential modification by at least two distinct cyclin-cdk
complexes. Mol Cell Biol 18: 753–761.
13. Beijersbergen RL, Carlee L, Kerkhoven RM, Bernards R (1995) Regulation of
the retinoblastoma protein-related p107 by G1 cyclin complexes. Genes Dev 9:
1340–1353.
14. Xiao ZX, Ginsberg D, Ewen M, Livingston DM (1996) Regulation of the
retinoblastoma protein-related protein p107 by G1 cyclin-associated kinases.
Proc Natl Acad Sci U S A 93: 4633–4637.
15. Bruce JL, Hurford RK Jr, Classon M, Koh J, Dyson N (2000) Requirements for
cell cycle arrest by p16INK4a. Mol Cell 6: 737–742.
16. Cheng L, Rossi F, Fang W, Mori T, Cobrinik D (2000) Cdk2-dependent
phosphorylation and functional inactivation of the pRB-related p130 protein in
pRB(2), p16INK4A(+) tumor cells. J Biol Chem 275: 30317–30325.
17. Gaubatz S, Lindeman GJ, Ishida S, Jakoi L, Nevins JR, et al. (2000) E2F4 and
E2F5 play an essential role in pocket protein-mediated G1 control. Mol Cell 6:
729–735.
18. Hansen K, Farkas T, Lukas J, Holm K, Ronnstrand L, Bartek J (2001)
Phosphorylation-dependent and -independent functions of p130 cooperate to
evoke a sustained G1 block. Embo J 20: 422–432.
19. Farkas T, Hansen K, Holm K, Lukas J, Bartek J (2002) Distinct phosphorylation
events regulate p130- and p107-mediated repression of E2F-4. J Biol Chem 277:
26741–26752.
20. Leng X, Noble M, Adams PD, Qin J, Harper JW (2002) Reversal of growth
suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent
kinase 4. Mol Cell Biol 22: 2242–2254.
21. Raucci A, Laplantine E, Mansukhani A, Basilico C (2004) Activation of the
ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast
growth factor-induced growth arrest of chondrocytes. J Biol Chem 279:
1747–1756.
22. Coleman KG, Wautlet BS, Morrissey D, Mulheron J, Sedman SA, et al. (1997)
Identification of CDK4 sequences involved in cyclin D1 and p16 binding. J Biol
Chem 272: 18869–18874.
23. Zhao Q, Boschelli F, Caplan AJ, Arndt KT (2004) Identification of a conserved
sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4. J Biol
Chem 279: 12560–12564.
24. Swingle M, Ni L, Honkanen RE (2007) Small-molecule inhibitors of ser/thr
protein phosphatases: specificity, use and common forms of abuse. Methods Mol
Biol 365: 23–38.
25. Arroyo JD, Hahn WC (2005) Involvement of PP2A in viral and cellular
transformation. Oncogene 24: 7746–7755.
26. Cicchillitti L, Fasanaro P, Biglioli P, Capogrossi MC, Martelli F (2003)
Oxidative stress induces protein phosphatase 2A-dependent dephosphorylation
of the pocket proteins pRb, p107, and p130. J Biol Chem 278: 19509–19517.
27. Voorhoeve PM, Hijmans EM, Bernards R (1999) Functional interaction
between a novel protein phosphatase 2A regulatory subunit, PR59, and the
retinoblastoma-related p107 protein. Oncogene 18: 515–524.
28. Vuocolo S, Purev E, Zhang D, Bartek J, Hansen K, et al. (2003) Protein
phosphatase 2A associates with Rb2/p130 and mediates retinoic acid-induced
growth suppression of ovarian carcinoma cells. J Biol Chem 278: 41881–41889.
29. Garriga J, Jayaraman AL, Limon A, Jayadeva G, Sotillo E, et al. (2004) A
dynamic equilibrium between CDKs and PP2A modulates phosphorylation of
pRB, p107 and p130. Cell Cycle 3: 1320–1330.
30. Magenta A, Fasanaro P, Romani S, Di Stefano V, Capogrossi MC, et al. (2008)
Protein phosphatase 2A subunit PR70 interacts with pRb and mediates its
dephosphorylation. Mol Cell Biol 28: 873–882.
31. Janssens V, Goris J (2001) Protein phosphatase 2A: a highly regulated family of
serine/threonine phosphatases implicated in cell growth and signalling.
Biochem J 353: 417–439.
32. Pallas DC, Shahrik LK, Martin BL, Jaspers S, Miller TB, et al. (1990) Polyoma
small and middle T antigens and SV40 small t antigen form stable complexes
with protein phosphatase 2A. Cell 60: 167–176.
33. Yang SI, Lickteig RL, Estes R, Rundell K, Walter G, et al. (1991) Control of
protein phosphatase 2A by simian virus 40 small-t antigen. Mol Cell Biol 11:
1988–1995.
34. Mungre S, Enderle K, Turk B, Porras A, Wu YQ, et al. (1994) Mutations which
affect the inhibition of protein phosphatase 2A by simian virus 40 small-t antigen
in vitro decrease viral transformation. J Virol 68: 1675–1681.
35. Strack S, Cribbs JT, Gomez L (2004) Critical role for protein phosphatase 2A
heterotrimers in mammalian cell survival. J Biol Chem 279: 47732–47739. Epub
42004 Sep 47739.
36. Arnold HK, Sears RC (2006) Protein phosphatase 2A regulatory subunit
B56alpha associates with c-myc and negatively regulates c-myc accumulation.
Mol Cell Biol 26: 2832–2844.
37. Kleinberger T, Shenk T (1993) Adenovirus E4orf4 protein binds to protein
phosphatase 2A, and the complex down regulates E1A-enhanced junB
transcription. J Virol 67: 7556–7560.
38. Shtrichman R, Sharf R, Kleinberger T (2000) Adenovirus E4orf4 protein
interacts with both Balpha and B9 subunits of protein phosphatase 2A, but
E4orf4-induced apoptosis is mediated only by the interaction with Balpha.
Oncogene 19: 3757–3765.
39. Harbour JW, Dean DC (2000) The Rb/E2F pathway: expanding roles and
emerging paradigms. Genes Dev 14: 2393–2409.
40. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, et al. (2002) E2F integrates
cell cycle progression with DNA repair, replication, and G(2)/M checkpoints.
Genes Dev 16: 245–256.
41. Moroy T, Geisen C (2004) Cyclin E. Int J Biochem Cell Biol 36: 1424–1439.
42. Yeh N, Miller JP, Gaur T, Capellini TD, Nikolich-Zugich J, et al. (2007)
Cooperation between p27 and p107 during endochondral ossification suggests a
genetic pathway controlled by p27 and p130. Mol Cell Biol 27: 5161–5171.
43. Dailey L, Ambrosetti D, Mansukhani A, Basilico C (2005) Mechanisms
underlying differential responses to FGF signaling. Cytokine Growth Factor
Rev 16: 233–247. Epub 2005 Mar 2005.
44. Sahni M, Ambrosetti DC, Mansukhani A, Gertner R, Levy D, et al. (1999) FGF
signaling inhibits chondrocyte proliferation and regulates bone development
through the STAT-1 pathway. Genes Dev 13: 1361–1366.
p107 Dephosphorylation by PP2A
PLoS ONE | www.plosone.org 11 October 2008 | Volume 3 | Issue 10 | e344745. Priore R, Dailey L, Basilico C (2006) Downregulation of Akt activity contributes
to the growth arrest induced by FGF in chondrocytes. J Cell Physiol 207:
800–808.
46. Krucher NA, Rubin E, Tedesco VC, Roberts MH, Sherry TC, et al. (2006)
Dephosphorylation of Rb (Thr-821) in response to cell stress. Exp Cell Res 312:
2757–2763.
47. Mukhopadhyay K, Lefebvre V, Zhou G, Garofalo S, Kimura JH, et al. (1995)
Use of a new rat chondrosarcoma cell line to delineate a 119-base pair
chondrocyte-specific enhancer element and to define active promoter segments
in the mouse pro-alpha 1(II) collagen gene. J Biol Chem 270: 27711–27719.
p107 Dephosphorylation by PP2A
PLoS ONE | www.plosone.org 12 October 2008 | Volume 3 | Issue 10 | e3447